CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...